» Articles » PMID: 9174212

Time-kill Curves for a Semisynthetic Glycopeptide, LY333328, Against Vancomycin-susceptible and Vancomycin-resistant Enterococcus Faecium Strains

Overview
Specialty Pharmacology
Date 1997 Jun 1
PMID 9174212
Citations 5
Authors
Affiliations
Soon will be listed here.
Citing Articles

Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Boylan C, Campanale K, Iversen P, Phillips D, Zeckel M, Parr Jr T Antimicrob Agents Chemother. 2003; 47(5):1700-6.

PMID: 12709343 PMC: 153305. DOI: 10.1128/AAC.47.5.1700-1706.2003.


Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.

Zelenitsky S, Booker B, Laing N, Karlowsky J, Hoban D, Zhanel G Antimicrob Agents Chemother. 1999; 43(3):592-7.

PMID: 10049272 PMC: 89165. DOI: 10.1128/AAC.43.3.592.


Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Saleh-Mghir A, Lefort A, Petegnief Y, Dautrey S, Vallois J, Le Guludec D Antimicrob Agents Chemother. 1998; 43(1):115-20.

PMID: 9869575 PMC: 89030. DOI: 10.1128/AAC.43.1.115.


In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

Garcia-Garrote F, Cercenado E, Alcala L, Bouza E Antimicrob Agents Chemother. 1998; 42(9):2452-5.

PMID: 9736584 PMC: 105854. DOI: 10.1128/AAC.42.9.2452.


Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Kaatz G, Seo S, Aeschlimann J, Houlihan H, Mercier R, Rybak M Antimicrob Agents Chemother. 1998; 42(4):981-3.

PMID: 9559828 PMC: 105587. DOI: 10.1128/AAC.42.4.981.